Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ANI Pharmaceuticals Stock Down 3.5 %

ANIP traded down $1.95 on Wednesday, reaching $53.88. The company’s stock had a trading volume of 198,776 shares, compared to its average volume of 221,746. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -97.96 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.00 and a fifty-two week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average of $58.00 and a two-hundred day moving average of $60.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same period in the previous year, the company earned $1.05 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 12.5% compared to the same quarter last year. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Franklin Resources Inc. increased its stake in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 691 shares during the period. Hohimer Wealth Management LLC acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $264,000. Geode Capital Management LLC raised its stake in ANI Pharmaceuticals by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after acquiring an additional 17,314 shares during the last quarter. Barclays PLC lifted its position in ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after acquiring an additional 135,003 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $405,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ANIP shares. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.